<mods:mods xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" version="3.3" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><mods:titleInfo><mods:title>CARDIOMETABOLIC SYNDROME: THE IMPACT OF DIABETES,  HYPERTENSION, AND OBESITY ON CARDIOVASCULAR DISEASES</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Mingaliyeva Shaxrizoda Dilmurod</mods:namePart><mods:namePart type="family">qizi</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Rajabaliyeva Mohruhsor Amandullo</mods:namePart><mods:namePart type="family">qizi</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Cardiometabolic syndrome is a complex pathological condition characterized by the coexistence of diabetes, hypertension, and obesity, significantly increasing the risk of developing cardiovascular diseases. This article analyzes the pathophysiological mechanisms of cardiometabolic syndrome, including insulin resistance, inflammatory processes, and dyslipidemia, and their impact on heart function. Additionally, strategies for disease prevention and treatment, including lifestyle modifications, pharmacological approaches, and current clinical recommendations, are discussed. The research findings highlight the necessity of developing effective preventive and therapeutic measures against cardiometabolic syndrome.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2025-02-25</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>Research Science and Innovation House</mods:publisher></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>